Clinical Trial Update: A Study of the Safety, Tolerability and Preliminary Efficacy of B2065 in Patients With Acute Ischemic Stroke. [Phase 1, Phase 2]

View source ↗

Summary

Tasly's B2065 is being studied for safety, tolerability and preliminary efficacy in acute ischemic stroke. The Phase 1/2 trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• B2065

Snippet

Sponsor: Tasly Pharmaceutical Group Co., Ltd | Conditions: Acute Ischemic Stroke | Phase 1, Phase 2 | Status: RECRUITING